Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.82 |
| ▸ | F10 | P00742 | 14/20 | 0.82 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.59 |
| ▸ | F12 | P00748 | 2/20 | 0.57 |
| ▸ | F7 | P08709 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236176 | 0.85 | F2 (0.84) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL14944056 | 0.85 | F2 (0.84) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL8242108 | 0.84 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6925356 | 0.81 | F2 (0.75) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL8237475 | 0.77 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL17222132 | 0.76 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL17222130 | 0.76 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6920896 | 0.76 | F2 (0.75) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL8243313 | 0.76 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL19390321 | 0.76 | F2 (0.78) | F2F10PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926743-B1 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa | MEDICINES CO LEIPZIG GMBH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-8124587-B2 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124587-B2 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2009-05-07 | — | — | US | disclosed |
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2009-05-07 | — | — | US | disclosed |
| WO-2007031343-A1 | 2-(AMINOMETHYL)-5-CHLOROBENZYLAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CLOTTING FACTOR Xa | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | F2, F11, TFPI | F2 1/4885F10 5/4885PRSS1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.